Jaume Capdevila

Precision-driven care in #neuroendocrine carcinoma starts with accurate diagnosis and informed treatment planning. Watch this #MedEd activity to review DLL3 biology, investigational DLL3-directed therapies, and practical strategies for patient management: bit.ly/40m8aY9 #Oncology @Ja_Capdevila

🎨 Cuando el arte impulsa la investigación en cáncer de páncreas. Del 08/07 al 20/07, únete a la subasta online de obras de Esperanza Pérez Calvo, en colaboración con Arce Auctions. Los fondos se destinarán a la investigación del Grupo de Cáncer Hepatobiliar, Pancreático y Tumores Endocrinos del #VHIO, liderado por @Ja_Capdevila 🖼️ Descubre las obras y participa ➡️ linke.to/SubastaEsperan… ℹ️ Más información 🔗 linke.to/NotiEsperanzaA…

💙 El Festival Vallviva, impulsado por la Fundación Eudald Morera, ha recaudado 60.000 € para la investigación contra el cáncer en @VHIR_ y @VHIO en las últimas tres ediciones, reforzando su compromiso con la investigación del Campus @vallhebron En VHIO, los fondos impulsarán un proyecto sobre cáncer de páncreas avanzado liderado por @Ja_Capdevila. ➡️  linke.to/VallvivaVHIOVH…

EMA fast tracks review of a medicine for metastatic pancreatic cancer buff.ly/nfdmVDb The EMA’s CHMP has initiated a phased review of daraxonrasib, a potential treatment for previously treated metastatic #PancreaticCancer . Based on phase 3 data, this approach aims to accelerate evaluation while maintaining rigorous quality, safety, and efficacy standards. Recognized through the Cancer Medicines Pathfinder for addressing high unmet need, daraxonrasib represents a new regulatory pathway designed to enable faster patient access to promising oncology therapies. Pinging our OncoAlert GI Cancer Faculty 🚨 @CathyEngMD @BenWestphalen @graokane @NiuSanford @AndresC27622123 @GillSharlene @pashtoonkasi @DrVilmaPBarcia @Erman_Akkus @GIMedOnc @UOzkerim @MarioBalsaMD @p_ciracimd @DraMartinezLago @DaisukeKotani @Aiims1742 @ARosen380 @realbowtiedoc @KoheiShitara @fumikochino @HenningWillers @_ShankarSiva

🔥CRISPR in clinical oncology: from molecular diagnostics to therapeutics 🆙 @NatRevClinOncol 🎯CRISPR-Cas systems extend therapeutic reach to undruggable targets via in vivo editing 🎯Delivery, safety & regulatory frameworks are key challenges for clinical translation 🎙Dr. Samuel Grigg @OncoAlert @Larvol nature.com/articles/s4157…

🎨 Quan l’art impulsa la recerca en càncer de pàncrees. Uneix-te en la subhasta online d’obres d’Esperanza Pérez Calvo, en col·laboració amb Arce Auctions. 🗓️ 08/07 al 20/07 Els fons es destinaran a la recerca del Grup de Càncer Hepatobiliar, Pancreàtic i Tumors Endocrins del #VHIO, liderat per @Ja_Capdevila 🖼️ Descobreix les obres i participa-hi ➡️ linke.to/SubastaEsperan… ℹ️ Més informació 🔗 linke.to/NotiEsperanzaA…

Read now in #JCO! "Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial." Co-authored by @GIcancerdoc. Read the article. bit.ly/4woAqYc

@TheLancet -Very important and well-designed study. -Mostly second-line (86%); Most Grade 2 (79%). -No concomitant SSA -Good choice of control here (arguably!) --Good PFS benefit and favorable QOL signal. I would argue that the true PFS difference might be even more profound. We all know everolimus is not easy: TEAEs led to study discontinuation in 23% vs 6% with PRRT. If a patient is not tolerating treatment and does not return for further scans, that patient may be censored at the last adequate assessment. This could leave a fitter subset in the everolimus arm and potentially inflate its PFS estimate. By 18 months, 29% of patients in the everolimus arm vs 15% in the PRRT arm had been censored. you can see the early imbalance. For more on informative censoring with everolimus, I recommend this read: jamanetwork.com/journals/jamao…) Looking forward to COMPOSE, which will evaluate the efficacy of this PRRT in higher-risk patients with better control than NETTER-2... Congrats @Ja_Capdevila and team #NET #PRRT

No todos los días se publica en @TheLancet Enhorabuena a la Dra @PaulaJFonseca 🤗 del @HUCA_Asturias @astursalud @FINBAsturias por su participación en el estudio COMPETE permitiendo avanzar y ofrecer oportunidades a los pacientes con GEP-TNEs. Y a todo el @GrupoGetne 👏👏👏

✨ Viu l'experiència Vallviva! 👏 No et perdis el Festival solidari sorgit de la voluntat de crear un espai de celebració, un punt de trobada i un esdeveniment únic al cor de la Garrotxa. 💙 Ajudes a la recerca de #VallHebron. Compra d'entrades: vallviva.koobin.cat

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial buff.ly/XK5LsTc The COMPETE phase 3 trial compared [177Lu]Lu-edotreotide with everolimus in patients with advanced, progressive somatostatin receptor-positive GEP NETs. In 309 randomized patients, peptide receptor radionuclide therapy significantly improved median progression-free survival (23.9 vs 14.1 months; HR 0.67) with a manageable safety profile. Grade 3–4 toxicities were less frequent than with everolimus. These findings support [177Lu]Lu-edotreotide as an effective early-line option in metastatic GEP NETs. @GCarboneroLab, @Ja_Capdevila, @louis_demestier Pinging OncoAlert GI faculty @pashtoonkasi @CathyEngMD @marklewismd @manjuggm @stacy_hurt @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen @graokane @NiuSanford OncoAlert AF @DrVilmaPBarcia @Erman_Akkus @GIMedOnc @UOzkerim @MarioBalsaMD @p_ciracimd @DraMartinezLago

🔬 Esta semana hemos conocido que el ensayo fase 3 #COMPETE demuestra que la terapia con radioligandos muestra beneficios en pacientes con un tipo de tumor neuroendocrino con pocas opciones terapéuticas.   ➡️ linke.to/COMPETETrialVH…

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial spkl.io/60197GeZF

El Festival Vallviva, impulsat per la Fundació Eudald Morera, recapta 60.000 € per la recerca en càncer a #VallHebron en les darreres 3 edicions i reforça el seu compromís amb la recerca del Campus. 💜 👉vhir.vallhebron.com/ca/societat/no…

🔬 Un estudi internacional liderat pel Dr. Jaume Capdevila, oncòleg mèdic de l'Hospital Universitari Vall d'Hebron i el @VHIO, aporta una nova opció de tractament per a les persones amb tumors neuroendocrins avançats.  L'estudi demostra que el nou tractament ajuda a mantenir la malaltia controlada durant més temps que els tractaments disponibles fins ara, un resultat que pot millorar les opcions terapèutiques dels pacients vallhebron.social/9be1U

🧠 SSTR-PeRForm v1.0: 1st ENETS Delphi framework for SSTR-PET response assessment in NETs. 📏 Volumetric criteria: ✅ PR: ≥40% reduction 📈 PD: ≥40% increase / new lesions 🔄 Introduces unconfirmed PD 🧩 A new SoC for SSTR-PET response assessment. 🔗 doi.org/10.1016/S1470-…

The question is no longer if KRAS inhibitors have a role in PDAC—it is how best to use them? Future research should focus on: 🧬 Optimal sequencing 💊 Rational combination strategies 🔄 Overcoming resistance 🎯 Biomarker-driven patient selection #ESMOGI26 #PDAC

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial - The Lancet thelancet.com/journals/lance…

🚨 COMPETE may change sequencing in advanced GEP NETs. First phase 3 head-to-head: ☢️ ¹⁷⁷Lu-edotreotide PRRT vs 💊 Everolimus Population: Advanced, progressive, SSTR+ G1-2 GEP NETs N=309 | 58% pancreatic | 85% second-line Key results 👇 ✅ PFS 23.9 vs 14.1 mo HR 0.67, p=0.022 ✅ ORR 22% vs 4% p<0.0001 ✅ QoL Decline with everolimus, preserved with PRRT ✅ Safety TR grade 3-4 AEs: 18% vs 40% OS immature: 63.4 vs 58.7 mo HR 0.78, p=0.21 Take-home: For progressive SSTR+ G1-2 GEP NETs, PRRT moves ahead of everolimus for disease control, response, QoL and tolerability. This is not just “another PRRT trial.” It is sequencing evidence. Full paper in first comment.

🧠 COMPETE reshapes the conversation. 🔄 Treatment sequencing matters. ☢️ Earlier PRRT may optimize disease control while preserving future treatment options in advanced SSTR+ GEP-NETs. 🔗 doi.org/10.1016/S0140-… @Ja_Capdevila @JHernando3 @GCarboneroLab @drdelolmo_mbel @PaulaJFonseca